Access Vascular, Medline Ink Deal for Cobranded Vascular Access Catheters

Access Vascular Inc. (AVI) and Medline began a multi-year agreement to speed the release of AVI’s next-gen catheters, HydroMID and HydroPICC, which recently earned an anti-thrombogenic indication from the U.S. Food and Drug Administration (FDA).

AVI’s HydroMID and HydroPICC catheters boast a proprietary hydrogel material with anti-thrombogenic properties to address the catheter-related complications of thrombosis and occlusion, which are possible sources of morbidity, readmissions, and cost for health systems.

Co-branded and co-developed products are anticipated to become available through Medline beginning in late 2026. They’ll be integrated into fully assemble, customizable procedure kits delivered to health systems nationwide, including Medline’s over 1,600 Prime Vendor customers.

Merging AVI’s biomaterial technology with Medline’s kitting and supply chain abilities helps deliver a streamlined, procedure-ready solution to help improve efficiency, support consistency in care, and bolster supply chain resiliency. The duo’s combined sales and clinical footprint are made of over 300 acute care reps working with a specialized, experienced vascular access team.

Comments from Medline, Access Vascular, and clinicians

James Biggins, CEO, Access Vascular: “Vascular access has needed a better solution for decades—we built a technology that significantly reduces device-replacement and complication rates based on real-world evidence, now we’re bringing it to hospitals across the U.S. with Medline. This partnership gives us the commercial reach to match our clinical ambition—from co-developing a customizable kitted solution to deploying it across a broad supply chain network. Most of all, I’m excited by how this accelerates our vision to bring innovation to clinicians and ultimately improve patient outcomes.”

Matthew Ostroff, RN, MSN, AGACNP-BC, VABC, vascular access coordinator, St. Joseph’s Health: “Reducing infection risk and improving catheter performance in vascular access has been a priority in our practice for years. Innovations that address those challenges—particularly without relying on chemical additives—are worth paying attention to. Solutions that can be scaled through broad distribution networks have the potential to set a new standard for performance and patient care, and that matters at the bedside every day. Collaborations like this have the potential to drive meaningful progress, giving clinicians the tools to reduce complications, improve efficiency, and consistently elevate the quality of care they deliver. That’s the kind of advancement our field needs.”

Vish Bhave, executive VP, Medline Brand: “Advancing vascular access requires both innovation and the ability to deliver it reliably at scale. This agreement allows us to pair clinically differentiated technology with our ability to deliver fully assembled, procedure-ready kits—helping health systems more seamlessly adopt solutions designed to address some of the most persistent challenges in vascular access.”